Organization
Margaret Ragni
3 clinical trials
Clinical trial
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize StudyStatus: Terminated, Estimated PCD: 2022-04-30
Clinical trial
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia AStatus: Terminated, Estimated PCD: 2022-04-06
Clinical trial
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia AStatus: Terminated, Estimated PCD: 2022-06-27